About us

In 2022, RVMC was launched by the World Economic Forum, the US National Academies of Medicine, and the Coalition for Epidemic Preparedness Innovations in response to a stark reality exposed by the pandemic: deep inequities in the global vaccine production system, with lower- and middle-income countries bearing the greatest burden.

Incubated at the World Economic Forum in partnership with Deloitte and co-chaired by NAM and CEPI, RVMC’s first phase focused on building momentum - bringing together a diverse community of partners, strengthening regional collaboration, and developing the RVMC Framework. This framework defines eight essential building blocks for creating resilient, sustainable, regional vaccine manufacturing ecosystems.

In January 2024, the founding partners reaffirmed their commitment, extending RVMC for another three years with strong backing from key regional stakeholders, including the Pan American Health Organization and the Africa CDC. CEPI now hosts the RVMC Secretariat and has committed USD 15 million to support its work.

By July 2024, the Secretariat unveiled its ambitious strategy for RVMC 2.0, setting a clear path forward across three priority regions: Africa, Latin America and the Caribbean, and Southeast Asia. The strategy is anchored in four core functions – advocating for RVM, aligning and convening partners, providing independent and trusted advice, and accounting for global and regional progress against the RVMC Framework.

Together, these roles define RVMC’s approach - collaborative, independent, and purposefully designed to enable and accelerate the actions of others.